NAB815

NAB815 is a specific inhibitor of Stx2a (Kd= 0.01 μM) /TLR4 interactions. It inhibits the interaction between neutrophils and Stx2a with an IC50 of 0.057 μg/mL. NAB815 also prevents the formation of extracellular vesicles (EV) containing Stx2 from leukocytes and platelets, reducing its toxicity in cells (Vero cells) and in animal models (CD-1 mice) . Additionally, NAB815 decreases the bacterial load in the kidneys, urine, and bladder of mice infected with Escherichia coli. It is applicable for research in hemolytic uremic syndrome (HUS) .